Recursion Pharmaceuticals, an emerging biotechnology company today announced it has hired Martin Brenner, DVM, Ph.D. as Chief Scientific Officer. Dr. Brenner joins the company after 17 years in the pharmaceutical industry, most recently as the VP and Head of Research & Pre-clinical Development at Stoke Therapeutics. Previously, he held the position of Executive Director at Merck where he founded a new research team and led the early Diabetes & NASH portfolio.
Dr. Brenner joins Recursion at an important juncture as the company has validated and is scaling its innovative AI-enabled drug discovery platform and prepares to advance over 100 therapeutic programs through early discovery and into preclinical development. With over a decade of drug discovery experience at world-class pharmaceutical companies such as Eli Lilly, AstraZeneca, Pfizer and Merck, Dr. Brenner brings deep industry experience and distinguished scientific leadership to the Recursion team. Under the scientific leadership of Dr. Brenner, Recursion will continue to expand its innovative biology discovery platform into new therapeutic areas such as Immunology, Oncology, and Cardiovascular & Metabolic, and advance treatments for dozens of genetic diseases to patients with unmet medical need.
“We're thrilled to have Martin join the team, as his rich drug discovery experience and demonstrated ability to build high-functioning scientific teams will have a major impact on our short-term success as we seek to translate our first discoveries to the clinic,” said Chris Gibson, co-founder, and CEO of Recursion.